• Dr. Farhan Mohammad MD

Acute promyelocytic leukemia (APL) in a patient with Crohn's disease and exposure to infliximab: a

Farhan Mohammad,1 Abhirami Vivekanandarajah,1 Housam Haddad,1 Christopher M Shutty,2 Matthew T Hurford, 2 and Qun Dai 1


With the introduction of potent immunosuppressive and chemotherapeutic medications for various diseases, there is an increased incidence of therapy-related myeloid neoplasms. They are the result of mutational rearrangement and historically, have a grave prognosis compared with de novo myeloid neoplasms. We did a short review on various types of myeloid leukemias reported after therapy with antitumor necrosis factor and also report, to the best of our knowledge, one among the very few cases of therapy-related acute promyelocytic leukemia in a patient on infliximab therapy for refractory Crohn's disease. The patient responded well to the traditional treatment and is in complete remission for more than 5 years. Background It is a very rare and possibly one of the few case reports of acute promyelocytic leukemia (APL; acute myeloid leukemia M3, AML-M3) to be reported in a patient with refractory Crohn's disease on maintenance infliximab therapy. Full Article: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039892/